本报告描述了一名 48 岁女性的病例，她在服用治疗小细胞肺癌的免疫检查点抑制剂 (ICI) durvalumab 后出现胸锁关节关节炎。关节炎在 ICI 治疗方案开始 18 个月后出现，并表现出对糖皮质激素治疗的恢复能力。排除感染性病因和转移灶后，患者被诊断为 ICI 诱发性关节炎 (ICI-IA)。考虑到类似于 SAPHO 综合征的关节影响，患者接受了英夫利昔单抗治疗，结果完全缓解。这一发现意味着生物 DMARD 可以作为 ICI 诱导的胸锁关节关节炎的有效干预措施。鉴于其发病机制的异质性，治疗药物的选择可能需要根据每个病例的不同临床表现进行定制。版权所有 © 2024 Kachi、Sumitomo、Oka、Hata 和 Ohmura。

This report describes the case of a 48-year-old woman who presented with sternoclavicular joint arthritis after administration of an immune checkpoint inhibitor (ICI), durvalumab, for small cell lung carcinoma. The onset of arthritis transpired 18 months after the commencement of the ICI therapeutic regimen and demonstrated resilience to glucocorticoid treatment. After excluding infectious aetiologies and metastatic involvement, the patient was diagnosed with ICI-induced arthritis (ICI-IA). Considering the articular implications akin to the SAPHO syndrome, the patient was treated with infliximab, resulting in complete resolution. This finding implies that biological DMARDs can serve as effective interventions for ICI-induced sternoclavicular joint arthritis. Given the heterogeneous nature of its pathogenesis, the selection of therapeutic agents may require customization based on the distinct clinical presentation of each individual case.Copyright © 2024 Kachi, Sumitomo, Oka, Hata and Ohmura.